香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681) 自願公告 訂立戰略合作協議以拓展日本及東南亞市場及 搭建老年人AI數字健康一體化平台 本公告由腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，旨在使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣佈，本公司已於近日與東京生活館株式會社 (Tokyo Lifestyle Co., Ltd)（「Tokyo Lifestyle」或「合作方」）訂立戰略合作協議（「本 協議」）。雙方將圍繞認知障礙數字療法與功能健康品的深度融合，在日本及東南 亞等地區共同探索「線上認知能力檢測及訓練康復+線下功能健康品有機結合」的 一體化平台模式，致力於為老年人搭建AI數字健康一體化平台。 一、合作方介紹 東京生活館 ...

Group 1: Market Overview - The Hong Kong stock market experienced a V-shaped rebound, closing up 37 points or 0.14% at 26,885 after a significant drop earlier in the day, indicating that negative news has been digested and the market may return to 27,000 [3] - The Hang Seng Index opened lower, dropping as much as 436 points before recovering, with a total trading volume of 315.12 billion [3] Group 2: Company Performance - Among 88 blue-chip stocks, 61 saw an increase, with notable recoveries in technology stocks such as Tencent, which closed up 0.1% at 558.5, and Xiaomi, which rose 2.8% to 34.92 [4] - MGM China reported a net revenue of USD 1.236 billion for the last three months of the previous year, a year-on-year increase of 21.37%, with adjusted EBITDAR rising by 30.46% [9] Group 3: Industry Dynamics - Goldman Sachs noted an escalation in competition within China's consumer AI sector, predicting that major platforms like Tencent, Alibaba, and ByteDance will dominate the market [6] - The report highlights that Alibaba's strengths lie in its integration of e-commerce and local services, while Tencent's success will depend on the integration speed of its AI features within WeChat [6] - The Chinese gold consumption decreased by 3.57% year-on-year in 2025, marking the second consecutive year of decline, with jewelry consumption dropping significantly while gold bars and coins saw an increase [7]

Market Overview - The Hang Seng Index opened lower but managed to close up by 0.14% [1] - The geopolitical situation remains stable, with Iran set to negotiate nuclear issues with the U.S. on February 6 [1] - Gold and silver prices fell significantly, with silver dropping over 14% and gold falling more than 2% to below $4,900 per ounce [1] International Relations - Russian President Putin plans to visit China in the first half of 2026 following a video call with Chinese leaders [2] - U.S. and Chinese leaders had a positive discussion regarding regional issues and economic cooperation, with a planned visit by Trump to China in April [2] - China has requested state-owned enterprises to pause new investment projects in Panama [2] Technology Sector - Despite declines in U.S. tech stocks, some Chinese tech companies like Naxin Micro (02676) reported strong earnings and plan to raise product prices by 10%-25% [3] - Baidu (09888) announced a stock buyback plan of up to $5 billion and plans to introduce a dividend policy by 2026, leading to a nearly 3% increase in its stock price [3] - Xiaomi (01810) repurchased shares worth HKD 146 million, also seeing a nearly 3% rise [3] - Tencent (00700) is expected to maintain double-digit growth in its gaming business by 2026, with advertising revenue projected to grow around 20% [3] Consumer Sector - Kweichow Moutai (600519.SH) has shown strong performance, boosting consumer valuations [4] - Oriental Selection (01797) surged over 10% due to its unique brand and membership model [4] - Pop Mart (09992) reported significant demand for its new products, with resale prices on secondary markets showing substantial premiums [4] Restaurant Sector - Yum China (09987) reported total revenue of $11.797 billion for 2025, a 4% increase year-on-year, with net profit rising by 2% [5] - Haidilao (06862) is seeing positive impacts from the return of its founder, with plans for expansion and new brand growth [5] - Brainstorm Aurora-B (06681) announced a strategic partnership to promote digital health products in Southeast Asia, with a significant stock price increase of over 15% [6] Energy Sector - The U.S. is experiencing a surge in natural gas power generation capacity, with over 29 GW under construction, but many projects may face delays due to a lack of available gas turbines [7] - Companies like Eagle Precision (01286) and Dongfang Electric (01072) are positioned to benefit from this trend, with expectations of increased demand for gas turbine components [7] Aviation Sector - Cirrus Aircraft (02507) launched the new G3 Vision Jet, enhancing its product line and expected to improve profit margins [8] - The new jet model is designed for private and corporate users, featuring significant upgrades in safety and comfort [8] - Cirrus is projected to deliver approximately 800 aircraft in 2025, with new orders expected to reach around 600 units [9]

Core Viewpoint - The company Brainstorm Cell Therapeutics (06681) has seen a stock increase of over 13% following the announcement of a strategic partnership with Silk Road Technology Co., Ltd. to expand its digital therapy products in Malaysia and Southeast Asia [1] Group 1 - The strategic cooperation agreement aims to localize, promote, and transform research related to cognitive impairment digital therapy products in the Malaysian and Southeast Asian markets [1] - The board believes this partnership marks the company's official entry into the Malaysian market, further expanding its Southeast Asian business network [1] - The collaboration is expected to leverage the company's validated digital therapy experience and technology from the Chinese market to enhance its brand influence and business coverage internationally [1]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Silk Road Technology Co., Ltd. to promote the localization, market promotion, and scientific transformation of cognitive impairment digital therapy products in Malaysia and Southeast Asia [1] Group 1: Strategic Cooperation - The agreement includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia [1] - Silk Road Technology will assist the company in coordinating local approvals, site planning, and equipment importation [1] - The company will provide technical solutions and research support, leading the research and operational aspects [1]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Silk Road Voyager Technology Co., Ltd. to promote the localization and market development of cognitive impairment digital therapy products in Malaysia and Southeast Asia, aiming to advance the digital health industry [1] Group 1: Cooperation Details - The cooperation includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road Voyager assisting in local approvals and logistics while the company provides technical solutions and research support [2] - Silk Road Voyager will lead the application for national innovation pilot projects in Malaysia, facilitating the joint implementation of these projects [2] - The partnership will involve selecting target hospitals for clinical pilot agreements, with the company responsible for product localization, training, and data collection [2] - Both parties will collaborate on market promotion and commercialization in Malaysia by integrating resources such as products, channels, and brands [2] - The cooperation will serve as a foundation for expanding into other Southeast Asian countries like Indonesia, Thailand, and Vietnam [2] Group 2: Long-term Development Opportunities - The collaboration is expected to deepen the company's international presence and expand its overseas market, marking its entry into Malaysia and enhancing its business network in Southeast Asia [3] - By leveraging local resources, the partnership aims to accelerate market entry and improve commercial conversion efficiency through Silk Road Voyager's extensive government and healthcare network in Malaysia [3] - The cooperation will enhance the company's brand authority and professional image in the digital healthcare sector, facilitating faster product integration into local medical institutions and expanding into diverse markets such as digital health management [3]

Group 1 - The core viewpoint of the article highlights that Brainstorm Cell Therapeutics (06681) has seen a significant stock price increase, rising over 8% during trading and currently up 5.87% to HKD 6.67, with a trading volume of HKD 110 million [1] - The company announced a strategic cooperation agreement with Singapore's Laheyspring Health Management Group to promote product marketing and market expansion in Singapore, aiming to advance the digital health industry [1] - In terms of product promotion, the company will localize and implement its cognitive impairment digital therapy products in Singapore, providing system support and personnel training, while Laheyspring will leverage its offline stores and member resources to recommend the company's products to target users [1] Group 2 - For market expansion collaboration, both parties will integrate resources such as products, channels, brands, and technology to jointly explore the Singapore market, focusing on introducing the company's products into leading private and public hospitals in Singapore to enhance their application and popularity within the local healthcare system [1]

Core Viewpoint - The company, Brainstorm Cell Therapeutics (脑动极光-B), has seen its stock price increase by over 8% during trading, currently up by 5.87% at HKD 6.67, with a trading volume of HKD 110 million, following the announcement of a strategic partnership with Singapore's Lehe Health Management Group [1] Group 1: Strategic Partnership - The company has entered into a strategic cooperation agreement with Lehe Health Management Group to promote and expand its products in the Singapore market [1] - The collaboration will focus on the localization, system implementation, and personnel training support for cognitive impairment digital therapy products in Singapore [1] - Lehe Health Management Group will utilize its offline stores and member resources to target users for the company's products, providing comprehensive services including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate their resources in products, channels, branding, and technology to jointly explore the Singapore market [1] - The partnership aims to facilitate the entry of the company's products into leading private and public hospitals in Singapore, enhancing the application and popularity of its products within the local healthcare system [1]

Core Viewpoint - The company Brainstorm Aurora-B (06681) has entered a strategic cooperation agreement with Singapore's Lehasiba Health Management Group to promote and expand its digital health products in the Singapore market [1] Group 1: Strategic Cooperation - The agreement focuses on product promotion and market expansion collaboration in Singapore [1] - Brainstorm Aurora will localize its cognitive impairment digital therapy products, support system implementation, and provide personnel training [1] - Lehasiba will utilize its offline stores and member resources to recommend the company's products to target users and manage the entire service process, including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate resources such as products, channels, brands, and technology to jointly explore the Singapore market [1] - The collaboration aims to promote the company's products into leading private hospitals and public hospital systems in Singapore, enhancing the application and popularity of the products within the local healthcare system [1]

Group 1: Hong Kong Stocks - China Metallurgical Group (01618) rose nearly 7%, with institutions stating that the value of this resource-rich construction company needs urgent reassessment [1] - Rongchang Bio (09995) increased over 5%, as its innovative ophthalmic drug RC28 has been submitted for listing, following a partnership with Santen China [1] - Laikang Pharmaceutical-B (02105) surged nearly 6%, with a cumulative increase of 36% over the last three trading days, driven by positive preliminary results from the Phase I clinical MAD study of LAE102 [1] - UBTECH Robotics (09880) rose over 5%, with a report from CMB International recommending UBTECH as the top pick in the humanoid robot sector and raising its target price [1] - Innovent Biologics (09969) increased over 6%, as the company announced the first prescriptions for Tanshitumomab in several provinces [1] - BrainCo-B (06681) surged over 16%, benefiting from policy catalysts in the brain-computer interface industry, with its cognitive impairment digital therapy product having a first-mover advantage [1] - Yaoshi Bang (09885) rose over 10%, with high-margin business accelerating growth and POCT devices expected to see increased deployment in the second half of the year [1] - DCH Holdings (00179) fell over 7%, as Citigroup downgraded its investment rating from "Buy" to "Neutral," citing limited upside potential for the stock [1] - Minmetals Resources (01208) rose over 2%, planning to issue $500 million zero-coupon convertible bonds maturing in 2030 for overseas debt refinancing [1][2] Group 2: US Stocks - Alibaba (BABA.US) rose 4.65%, with Morgan Stanley reiterating an "Overweight" rating and raising the ADR target price from $165 to $200 [3] - Li Auto (LI.US) increased 3.57%, as the Li One officially commenced delivery at the Changzhou smart manufacturing base, with a report indicating that the i6 model's sales performance is expected to outperform the i8 [3] - JD.com (JD.US) rose 0.15%, announcing that the 2025 Double 11 shopping festival will start on October 9 at 8 PM, two days earlier than last year [3] - Xpeng Motors (XPEV.US) increased 1.76%, with the company announcing that the Xpeng MONA M03 has delivered a total of 180,000 units [3] - New Oriental (EDU.US) rose 4.38%, with a report indicating that the overall business development of the group is stabilizing [3] - Merus (MRUS.US) surged 35.97%, following an agreement with Danish biotech company Genmab for a cash acquisition at $97 per share [3] - Novo Nordisk (NVO.US) fell 0.20%, as Morgan Stanley downgraded its rating to "Sell" and reduced the target price from $99 to $47 [4] - MoonLake (MLTX.US) plummeted 89.93%, with trial results for its therapeutic drug falling far below expectations, leading to a significant target price cut by RBC [4] - TSMC (TSM.US) fell 0.05%, reaffirming that it has not engaged in discussions regarding potential investments or collaborations with any companies [4] - Micron Technology (MU.US) rose 4.22%, with Morgan Stanley predicting that the storage industry price increase cycle may continue into next year [4]